Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
18
GOVX Quote, Financials, Valuation and Earnings
Last price:
$0.18
Seasonality move
:
-7.01%
Day range:
$0.16 - $0.19
52-week range:
$0.12 - $2.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.79x
P/B ratio:
1.10x
Volume:
2.4M
Avg. volume:
2.5M
1-year change:
-91.96%
Market cap:
$5.4M
Revenue:
$4M
EPS (TTM):
-$1.89
Analysts' Opinion
-
Consensus RatingGeoVax Labs, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.63, GeoVax Labs, Inc. has an estimated upside of 5197.19% from its current price of $0.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $0.18.
Fair Value
-
According to the consensus of 4 analysts, GeoVax Labs, Inc. has 5197.19% upside to fair value with a price target of $9.63 per share.
GOVX vs. S&P 500
-
Over the past 5 trading days, GeoVax Labs, Inc. has underperformed the S&P 500 by -28.34% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
GeoVax Labs, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
GeoVax Labs, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter GeoVax Labs, Inc. reported revenues of --.
Earnings Growth
-
GeoVax Labs, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter GeoVax Labs, Inc. reported earnings per share of -$0.31.
Enterprise value:
388.5K
EV / Invested capital:
0.08x
Price / LTM sales:
0.79x
EV / EBIT:
--
EV / Revenue:
0.12x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-0.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.4M
Return On Assets:
-299.99%
Net Income Margin (TTM):
-754.69%
Return On Equity:
-433.69%
Return On Invested Capital:
-433.69%
Operating Margin:
-635.8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $3.1M | $3.4M | $2.8M | -- | |
| Gross Profit | -$66K | $3M | $2.4M | $2.8M | -$16.8K | |
| Operating Income | -$24.4M | -$24.5M | -$25.5M | -$5.9M | -$6.4M | |
| EBITDA | -$24.4M | -$24.4M | -$25.5M | -$5.8M | -$6.4M | |
| Diluted EPS | -$13.48 | -$9.24 | -$1.89 | -$0.91 | -$0.31 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $18.2M | $36.1M | $14.8M | $10.9M | $6.5M | |
| Total Assets | $18.3M | $38.6M | $16.2M | $11.1M | $6.7M | |
| Current Liabilities | $335.6K | $4.8M | $7.1M | $2.6M | $1.8M | |
| Total Liabilities | $335.6K | $6.8M | $7.1M | $2.6M | $1.8M | |
| Total Equity | $18M | $31.8M | $9.1M | $8.5M | $4.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$22M | -$27.2M | -$24.3M | -$9.3M | -$6.2M | |
| Cash From Investing | -$30K | -$39.6K | -$27.6K | -$20.7K | -- | |
| Cash From Financing | -- | $23.1M | $20.7M | $16.3M | $8.1M | |
| Free Cash Flow | -$22M | -$27.2M | -$24.3M | -$9.3M | -$6.2M | |
GOVX
Sector
Market Cap
$5.4M
$28.1M
Price % of 52-Week High
6.61%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-147.17%
-1.49%
1-Year Price Total Return
-91.96%
-17.13%
Beta (5-Year)
3.638
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.25
200-day SMA
Sell
Level
$0.77
Bollinger Bands (100)
Sell
Level
0.41 - 0.71
Chaikin Money Flow
Sell
Level
-94.2M
20-day SMA
Sell
Level
$0.33
Relative Strength Index (RSI14)
Sell
Level
23.32
ADX Line
Sell
Level
38.11
Williams %R
Neutral
Level
-78.8639
50-day SMA
Sell
Level
$0.44
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
372.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-26.1577)
Sell
CA Score
(Annual)
Level (-12.7362)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (22.5614)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.
Stock Forecast FAQ
In the current month, GOVX has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GOVX average analyst price target in the past 3 months is $9.63.
-
Where Will GeoVax Labs, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that GeoVax Labs, Inc. share price will rise to $9.63 per share over the next 12 months.
-
What Do Analysts Say About GeoVax Labs, Inc.?
Analysts are divided on their view about GeoVax Labs, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GeoVax Labs, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is GeoVax Labs, Inc.'s Price Target?
The price target for GeoVax Labs, Inc. over the next 1-year time period is forecast to be $9.63 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GOVX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for GeoVax Labs, Inc. is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GOVX?
You can purchase shares of GeoVax Labs, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GeoVax Labs, Inc. shares.
-
What Is The GeoVax Labs, Inc. Share Price Today?
GeoVax Labs, Inc. was last trading at $0.18 per share. This represents the most recent stock quote for GeoVax Labs, Inc.. Yesterday, GeoVax Labs, Inc. closed at $0.18 per share.
-
How To Buy GeoVax Labs, Inc. Stock Online?
In order to purchase GeoVax Labs, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GOVX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GOVX
Sector
P/E ratio
--
23.89x
PEG ratio
-0.03x
-0.01x
P/B ratio
1.10x
1.81x
Price / LTM sales
0.79x
1.59x
Growth Metrics
GOVX
Sector
Revenue growth
-100%
4.62%
Earnings growth
65.69%
11.06%
Revenue (5-year growth)
27.45%
6.5%
Earnings forecast
--
-$0.21
Profitability
GOVX
Sector
Profitability FY 2024
$3.9M
$3.6M
Return on invested capital
-433.69%
-31.84%
Return on assets
-299.99%
-27.96%
Return on equity
-433.69%
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
12
Balance Sheet
GOVX
Sector
Total cash
$5M
$26.4M
Short term investments
--
$25.7M
Total assets
$8.2M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
